{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T08:35:10Z","timestamp":1776501310526,"version":"3.51.2"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Adjunctive lung resection is recommended for select patients with nontuberculous mycobacteria (NTM) pulmonary disease (PD). However, data are limited on long-term recurrence rates in patients infected with major pathogens, including Mycobacterium avium complex (MAC) and Mycobacterium abscessus (MABC).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this prospective observational study, we retrospectively analyzed data from 125 patients with MAC-PD (n = 90) or MABC-PD (n = 35) who underwent adjunctive lung resection. We evaluated microbiological response, postoperative complications, recurrence, and all-cause mortality over a median 80-month follow-up.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Persistent culture positivity (64%) was the most common indication for surgery, followed by hemoptysis, recurrent pneumonia, or radiologic deterioration. Postoperative complications occurred in 18 (14%) patients, with no surgery-related deaths. Treatment outcomes did not significantly differ between the MAC- and MABC-PD groups. Cure with culture conversion was achieved in 112 (90%) patients. Recurrence occurred in 37 (33%) of 112 patients, of which 18 (49%) cases were attributed to reinfection by different NTM species or subspecies. The MAC group had higher recurrence rates than the MABC group (Kaplan-Meier curve, log-rank test, P = .043) and was significantly associated with recurrence in the multivariable analysis (adjusted hazard ratio, 2.71; 95% CI, 1.23\u20135.99). However, mortality was higher in the MABC-PD group than the MAC-PD group (7\/35 vs 4\/90, P = .006).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Adjunctive lung resection with antibiotics helps to reduce bacterial burden and manage symptoms in patients with NTM-PD. However, it does not prevent recurrence, which is mostly caused by reinfection.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofae345","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T06:21:59Z","timestamp":1718691719000},"source":"Crossref","is-referenced-by-count":3,"title":["Long-term Outcomes of Adjunctive Lung Resection for Nontuberculous Mycobacteria Pulmonary Disease"],"prefix":"10.1093","volume":"11","author":[{"given":"Noeul","family":"Kang","sequence":"first","affiliation":[{"name":"Division of Allergy, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6348-8731","authenticated-orcid":false,"given":"Byung Woo","family":"Jhun","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,6,24]]},"reference":[{"key":"2024072916003951500_ofae345-B1","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ccm.2023.08.012","article-title":"Global epidemiology of nontuberculous mycobacterial pulmonary disease: a review","volume":"44","author":"Prevots","year":"2023","journal-title":"Clin Chest Med"},{"key":"2024072916003951500_ofae345-B2","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3201\/eid2503.181597","article-title":"Epidemiology of nontuberculous mycobacterial infection, South Korea, 2007\u20132016","volume":"25","author":"Lee","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"2024072916003951500_ofae345-B3","doi-asserted-by":"crossref","first-page":"2000535","DOI":"10.1183\/13993003.00535-2020","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"56","author":"Daley","year":"2020","journal-title":"Eur Respir J"},{"issue":"Suppl 2","key":"2024072916003951500_ofae345-B4","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/thoraxjnl-2017-210927","article-title":"British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)","volume":"72","author":"Haworth","year":"2017","journal-title":"Thorax"},{"key":"2024072916003951500_ofae345-B5","doi-asserted-by":"crossref","first-page":"e01206-17","DOI":"10.1128\/AAC.01206-17","article-title":"Systematic review and meta-analyses of the effect of chemotherapy on pulmonary Mycobacterium abscessus outcomes and disease recurrence","volume":"61","author":"Pasipanodya","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2024072916003951500_ofae345-B6","doi-asserted-by":"crossref","first-page":"1801991","DOI":"10.1183\/13993003.01991-2018","article-title":"Mycobacterium abscessus pulmonary disease: individual patient data meta-analysis","volume":"54","author":"Kwak","year":"2019","journal-title":"Eur Respir J"},{"key":"2024072916003951500_ofae345-B7","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/cid\/cix517","article-title":"Treatment outcomes of Mycobacterium avium complex lung disease: a systematic review and meta-analysis","volume":"65","author":"Kwak","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2024072916003951500_ofae345-B8","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.chest.2022.09.037","article-title":"Outcomes of adjunctive surgery in patients with nontuberculous mycobacterial pulmonary disease: a systematic review and meta-analysis","volume":"163","author":"Kim","year":"2023","journal-title":"Chest"},{"key":"2024072916003951500_ofae345-B9","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2024072916003951500_ofae345-B10","doi-asserted-by":"crossref","first-page":"1602503","DOI":"10.1183\/13993003.02503-2016","article-title":"Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype","volume":"50","author":"Koh","year":"2017","journal-title":"Eur Respir J"},{"key":"2024072916003951500_ofae345-B11","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/ciw724","article-title":"Mycobacterial characteristics and treatment outcomes in Mycobacterium abscessus lung disease","volume":"64","author":"Koh","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2024072916003951500_ofae345-B12","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.chest.2021.02.025","article-title":"Outcomes of inhaled amikacin-containing multidrug regimens for Mycobacterium abscessus pulmonary disease","volume":"160","author":"Kang","year":"2021","journal-title":"Chest"},{"key":"2024072916003951500_ofae345-B13","doi-asserted-by":"crossref","first-page":"e0077422","DOI":"10.1128\/aac.00774-22","article-title":"Outcomes of short-term tigecycline-containing regimens for Mycobacterium abscessus pulmonary disease","volume":"66","author":"Kim","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2024072916003951500_ofae345-B14","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12879-015-0823-1","article-title":"Treatment outcomes of adjuvant resectional surgery for nontuberculous mycobacterial lung disease","volume":"15","author":"Kang","year":"2015","journal-title":"BMC Infect Dis"},{"key":"2024072916003951500_ofae345-B15","doi-asserted-by":"crossref","first-page":"1800170","DOI":"10.1183\/13993003.00170-2018","article-title":"Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement","volume":"51","author":"van Ingen","year":"2018","journal-title":"Eur Respir J"},{"key":"2024072916003951500_ofae345-B16","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1164\/rccm.201807-1318OC","article-title":"Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT): a prospective, open-label, randomized study","volume":"198","author":"Griffith","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2024072916003951500_ofae345-B17","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.3390\/jcm10194581","article-title":"In vitro activity and clinical outcomes of clofazimine for nontuberculous mycobacteria pulmonary disease","volume":"10","author":"Kim","year":"2021","journal-title":"J Clin Med"},{"key":"2024072916003951500_ofae345-B18","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.jiac.2022.03.026","article-title":"Treatment outcome of continuation of intravenous amikacin for Mycobacterium abscessus pulmonary disease with a persistent culture positivity after the treatment initiation","volume":"28","author":"Park","year":"2022","journal-title":"J Infect Chemother"},{"key":"2024072916003951500_ofae345-B19","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.chest.2023.08.025","article-title":"Outcomes of intermittent multidrug IV therapy for refractory Mycobacterium abscessus pulmonary disease","volume":"165","author":"Im","year":"2024","journal-title":"Chest"},{"key":"2024072916003951500_ofae345-B20","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/cid\/cix274","article-title":"Long-term outcome of pulmonary resection for nontuberculous mycobacterial pulmonary disease","volume":"65","author":"Asakura","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2024072916003951500_ofae345-B21","doi-asserted-by":"crossref","first-page":"e0108822","DOI":"10.1128\/spectrum.01088-22","article-title":"Antibiotic maintenance and redevelopment of nontuberculous mycobacteria pulmonary disease after treatment of Mycobacterium avium complex pulmonary disease","volume":"10","author":"Zo","year":"2022","journal-title":"Microbiol Spectr"},{"key":"2024072916003951500_ofae345-B22","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1128\/AAC.04577-14","article-title":"Risk factors for recurrence after successful treatment of Mycobacterium avium complex lung disease","volume":"59","author":"Lee","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2024072916003951500_ofae345-B23","doi-asserted-by":"crossref","first-page":"eadi7558","DOI":"10.1126\/scitranslmed.adi7558","article-title":"An anti-mycobacterial conjugated oligoelectrolyte effective against Mycobacterium abscessus","volume":"16","author":"Zhang","year":"2024","journal-title":"Sci Transl Med"},{"key":"2024072916003951500_ofae345-B24","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiae100","article-title":"Metabolomic characteristics of nontuberculous mycobacterial pulmonary disease","author":"Kim","year":"2024","journal-title":"J Infect Dis"},{"key":"2024072916003951500_ofae345-B25","doi-asserted-by":"crossref","first-page":"e0311022","DOI":"10.1128\/spectrum.03110-22","article-title":"Decreased interleukin-1 family cytokine production in patients with nontuberculous mycobacterial lung disease","volume":"10","author":"Jung","year":"2022","journal-title":"Microbiol Spectr"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofae345\/58319338\/ofae345.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/7\/ofae345\/58649600\/ofae345.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/7\/ofae345\/58649600\/ofae345.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:01:31Z","timestamp":1722297691000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae345\/7696676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,24]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,6,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae345","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,6,24]]},"article-number":"ofae345"}}